Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

The corporate world is falling short in the fight against climate change

Only 20% of the top 1,000 companies have targets to reduce their emissions, a sign not enough leaders are taking climate change seriously.

Fortune

AstraZeneca sued over jab: could it be down to a misunderstanding of how risk is calculated?

A multi-million-pound landmark “vaccine damage” case is set to take place in London’s High Court. The test case is being pursued by Jamie Scott who suffered a severe brain injury in April 2021 after receiving the Oxford-AstraZeneca vaccine.

The Conversation

AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs

AZN stock popped after AstraZeneca said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca makes big push into weight-loss market with obesity pill deal

UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill

The Guardian - UK

FTSE 100 Live: London blue-chips climb, AstraZeneca results, Flutter and S4 Capital shares tumble

Shares in FTSE 100 heavyweight Diageo have tumbled after it cut guidance due to lower-than-expected demand in Latin America and the Caribbean.

Evening Standard

Why some people got blood clots after the AstraZeneca vaccine – new clues

AstraZeneca in partnership with the University of Oxford developed one of the first vaccines against COVID. The vaccine, which used an adenovirus to smuggle instructions into human cells to make antibodies against the novel coronavirus, saved countless lives. But a problem soon emerged. A tiny proportion – about one in…

The Conversation

We could see thunderstorm asthma in south-eastern Australia this season – here's how to prepare

Victorians have been warned to prepare for the possibility of thunderstorm asthma again this season.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

A new RSV shot for infants is in short supply

A new shot for infants against RSV is in short supply, and U.S. health officials are telling doctors they should prioritize giving the drug to babies at the highest risk of severe disease

The Independent UK

Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock

AstraZeneca stock tumbled Wednesday after its experimental drug led to only a month's benefit over chemotherapy in lung cancer patients.

Investors Business Daily

AstraZeneca Surges As It Takes A Shot At Gilead's Second-Biggest Cancer Drug

AstraZeneca and Daiichi Sankyo said Friday their breast cancer treatment outperformed chemo in a Phase 3 study, and AZN stock jumped.

Investors Business Daily

Scott Morrison is right: Any COVID inquiry that doesn’t look at state issues is meaningless

It might be the first time we’ve said this with no equivocation: Scott Morrison is absolutely right. Here are some major decisions in the management of COVID-19 the ALP doesn’t have an interest in looking into.

Crikey

UK ‘in danger of falling behind the pack’ in cancer research, MPs told

The Health and Social Care Committee heard from specialists in cancer research.

The Independent UK

AI analysis could help speed up heart failure detection, research suggests

It is estimated that more than a million people in the UK are living with heart failure.

The Independent UK

The top 100 bosses in the U.K. scored a pay hike of over $600k last year—the highest in six years

Among the highest paid CEOs were pharmaceutical giant AstraZeneca’s chief Pascal Soriot, with £15.3 million ($19.6 million), and defense company BAE Systems CEO Charles Woodburn, who earned £10.7 million ($13.7 million).

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Top UK CEOs handed 16% pay rise as millions of workers squeezed – as it happened

Data from the High Pay Centre thinktank showed FTSE 100 bosses collected an average £500,000 pay rise last year, taking their median pay to £3.9m

The Guardian - UK

FTSE 100 bosses ‘given average pay rise of £500,000 in 2022’

CEOs received average increase of 16% while pay of many working for them failed to keep up with inflation

Evening Standard

FTSE 100 Live: Shares fade, NatWest profits after CEO exit, AstraZeneca rises

NatWest has reported a big jump in half-year profits to £3.6 billion, days after Alison Rose stepped down as chief executive.

The Guardian - UK

Revealed: drug firms funding UK patient groups that lobby for NHS approval of medicines

Observer investigation shows that majority of Nice drug appraisals involve groups financially linked to maker of pharmaceuticals

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Pascal Soriot of AstraZeneca: ‘The climate crisis is a health crisis’

The man who led the drive to create a not-for-profit Covid vaccine is now focusing on the deaths caused by global heating and pollution

The Guardian - UK

Rishi Sunak to meet FTSE 100 bosses at new business council

Heads of 14 companies will meet prime minister to discuss how to attract more investment to the UK

The Independent UK

New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold season

U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year

The Guardian - UK

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

The Guardian - UK

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

Investors Business Daily

AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment

AstraZeneca and Daiichi Sankyo reported mixed results Monday from a final-phase study of their lung cancer treatment, and AZN stock tumbled.

The Guardian - UK

AstraZeneca stock value falls by nearly £14bn after cancer drug trial results

Shares close down 8% on concerns that new lung cancer drug may not be as successful as hoped

1 … 4 5 6 7

People

Annastacia Palaszczuk

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.